Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1992-11

AUTHORS

Stephanie Green, Geoffrey R. Weiss

ABSTRACT

The Southwest Oncology Group, in cooperation with the National Cancer Institute and the other major cooperative oncology groups, has participated in the development of new toxicity criteria for reporting the results of cancer clinical trials. The new criteria (NCI Common Toxicity Criteria) respond to a recognized need to: (1) report toxicities consistently among cooperative groups, particularly for shared 'intergroup' clinical trials; (2) strive for comparability in toxicity reporting among clinical trials; and (3) recognize new toxicities accompanying new classes of anticancer treatment modalities. The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. In addition, endpoint definitions and response criteria are discussed. These have been developed in response to previous uncertainties in clinical trials objectives, to limitations in the resolution of imaging methods, and to demands for greater rigor in response and endpoint definitions. Toxicity criteria, endpoint definitions, and response criteria are tabulated. More... »

PAGES

239-253

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00944177

DOI

http://dx.doi.org/10.1007/bf00944177

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017722235

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1487397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Southwest Oncology Group Statistical Center, 1124 Columbia Street, 98104, Seattle, Washington, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Green", 
        "givenName": "Stephanie", 
        "id": "sg:person.014014114517.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014014114517.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Health Science Center at San Antonio", 
          "id": "https://www.grid.ac/institutes/grid.267309.9", 
          "name": [
            "Department of Medicine, Division of Medical Oncology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78284, San Antonio, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weiss", 
        "givenName": "Geoffrey R.", 
        "id": "sg:person.013747706762.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013747706762.64"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1992-11", 
    "datePublishedReg": "1992-11-01", 
    "description": "The Southwest Oncology Group, in cooperation with the National Cancer Institute and the other major cooperative oncology groups, has participated in the development of new toxicity criteria for reporting the results of cancer clinical trials. The new criteria (NCI Common Toxicity Criteria) respond to a recognized need to: (1) report toxicities consistently among cooperative groups, particularly for shared 'intergroup' clinical trials; (2) strive for comparability in toxicity reporting among clinical trials; and (3) recognize new toxicities accompanying new classes of anticancer treatment modalities. The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. In addition, endpoint definitions and response criteria are discussed. These have been developed in response to previous uncertainties in clinical trials objectives, to limitations in the resolution of imaging methods, and to demands for greater rigor in response and endpoint definitions. Toxicity criteria, endpoint definitions, and response criteria are tabulated.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00944177", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2693350", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693495", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria", 
    "pagination": "239-253", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "547088923206db72ea270af3fc011f75572ea32adb31ba3546ae1fc0cf2cb72c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1487397"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00944177"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017722235"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00944177", 
      "https://app.dimensions.ai/details/publication/pub.1017722235"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000487.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00944177"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00944177'


 

This table displays all metadata directly associated to this object as RDF triples.

103 TRIPLES      20 PREDICATES      34 URIs      26 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00944177 schema:about N212b55d287ca4002a6491dbf742efae8
2 N6ca0dfe762e44aafb6f9d7c3793ce226
3 N7e481e10a72a4e07baecec3a4e7742d7
4 Na464809195e743478ca2b514ec9c46e7
5 Nb745ef1885dd4654bbe4be573143375a
6 anzsrc-for:11
7 anzsrc-for:1112
8 schema:author N1905d8fbdcaa47aeaedf1d072c80a865
9 schema:datePublished 1992-11
10 schema:datePublishedReg 1992-11-01
11 schema:description The Southwest Oncology Group, in cooperation with the National Cancer Institute and the other major cooperative oncology groups, has participated in the development of new toxicity criteria for reporting the results of cancer clinical trials. The new criteria (NCI Common Toxicity Criteria) respond to a recognized need to: (1) report toxicities consistently among cooperative groups, particularly for shared 'intergroup' clinical trials; (2) strive for comparability in toxicity reporting among clinical trials; and (3) recognize new toxicities accompanying new classes of anticancer treatment modalities. The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. In addition, endpoint definitions and response criteria are discussed. These have been developed in response to previous uncertainties in clinical trials objectives, to limitations in the resolution of imaging methods, and to demands for greater rigor in response and endpoint definitions. Toxicity criteria, endpoint definitions, and response criteria are tabulated.
12 schema:genre research_article
13 schema:inLanguage en
14 schema:isAccessibleForFree false
15 schema:isPartOf N2aa6626144054feca86073b8c68d968f
16 Nc7b1d33cd8fb4d69b824bf41238a418b
17 sg:journal.1094201
18 schema:name Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
19 schema:pagination 239-253
20 schema:productId N5c883ae9eb0e43558577f80bc7047511
21 N5f43a1c4bc2b4c7bb0ed617f4d998461
22 N7000ba0842c04667be696a65448a02f0
23 Nbe6c9f0606c741c78f75695f4b4c4bfb
24 Ncd33fc09e44149bba46c78c3d1f63774
25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017722235
26 https://doi.org/10.1007/bf00944177
27 schema:sdDatePublished 2019-04-10T15:45
28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
29 schema:sdPublisher Nc39adbde93c04eca8e54ff5a855e7b53
30 schema:url http://link.springer.com/10.1007/BF00944177
31 sgo:license sg:explorer/license/
32 sgo:sdDataset articles
33 rdf:type schema:ScholarlyArticle
34 N1905d8fbdcaa47aeaedf1d072c80a865 rdf:first sg:person.014014114517.46
35 rdf:rest Na5b331ce63de45f7a538eeaaac939cf7
36 N212b55d287ca4002a6491dbf742efae8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
37 schema:name Treatment Outcome
38 rdf:type schema:DefinedTerm
39 N2aa6626144054feca86073b8c68d968f schema:volumeNumber 10
40 rdf:type schema:PublicationVolume
41 N5c883ae9eb0e43558577f80bc7047511 schema:name doi
42 schema:value 10.1007/bf00944177
43 rdf:type schema:PropertyValue
44 N5f43a1c4bc2b4c7bb0ed617f4d998461 schema:name pubmed_id
45 schema:value 1487397
46 rdf:type schema:PropertyValue
47 N6ca0dfe762e44aafb6f9d7c3793ce226 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
48 schema:name Combined Modality Therapy
49 rdf:type schema:DefinedTerm
50 N7000ba0842c04667be696a65448a02f0 schema:name dimensions_id
51 schema:value pub.1017722235
52 rdf:type schema:PropertyValue
53 N7e481e10a72a4e07baecec3a4e7742d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Humans
55 rdf:type schema:DefinedTerm
56 Na464809195e743478ca2b514ec9c46e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Neoplasms
58 rdf:type schema:DefinedTerm
59 Na5b331ce63de45f7a538eeaaac939cf7 rdf:first sg:person.013747706762.64
60 rdf:rest rdf:nil
61 Nb745ef1885dd4654bbe4be573143375a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Remission Induction
63 rdf:type schema:DefinedTerm
64 Nbe6c9f0606c741c78f75695f4b4c4bfb schema:name readcube_id
65 schema:value 547088923206db72ea270af3fc011f75572ea32adb31ba3546ae1fc0cf2cb72c
66 rdf:type schema:PropertyValue
67 Nc39adbde93c04eca8e54ff5a855e7b53 schema:name Springer Nature - SN SciGraph project
68 rdf:type schema:Organization
69 Nc7b1d33cd8fb4d69b824bf41238a418b schema:issueNumber 4
70 rdf:type schema:PublicationIssue
71 Ncd33fc09e44149bba46c78c3d1f63774 schema:name nlm_unique_id
72 schema:value 8309330
73 rdf:type schema:PropertyValue
74 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
75 schema:name Medical and Health Sciences
76 rdf:type schema:DefinedTerm
77 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
78 schema:name Oncology and Carcinogenesis
79 rdf:type schema:DefinedTerm
80 sg:grant.2693350 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00944177
81 rdf:type schema:MonetaryGrant
82 sg:grant.2693495 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00944177
83 rdf:type schema:MonetaryGrant
84 sg:journal.1094201 schema:issn 0167-6997
85 1573-0646
86 schema:name Investigational New Drugs
87 rdf:type schema:Periodical
88 sg:person.013747706762.64 schema:affiliation https://www.grid.ac/institutes/grid.267309.9
89 schema:familyName Weiss
90 schema:givenName Geoffrey R.
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013747706762.64
92 rdf:type schema:Person
93 sg:person.014014114517.46 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
94 schema:familyName Green
95 schema:givenName Stephanie
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014014114517.46
97 rdf:type schema:Person
98 https://www.grid.ac/institutes/grid.267309.9 schema:alternateName The University of Texas Health Science Center at San Antonio
99 schema:name Department of Medicine, Division of Medical Oncology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78284, San Antonio, Texas, USA
100 rdf:type schema:Organization
101 https://www.grid.ac/institutes/grid.48336.3a schema:alternateName National Cancer Institute
102 schema:name Southwest Oncology Group Statistical Center, 1124 Columbia Street, 98104, Seattle, Washington, USA
103 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...